New drug aripiprazole of class 3.1 of Enhua pharmaceutical is undergoing three in one review, which is expected to be approved within this year
-
Last Update: 2014-10-21
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Aripiprazole is a new type of atypical antipsychotic drug, which was listed in China in 2004 Due to the remarkable curative effect on the positive and negative symptoms of schizophrenia, the products grow rapidly after being put on the market The compound growth rate of the drug was 41.16% in 2006-2010, and the domestic market scale was about 400 million by 2010 According to CFDA, at present, Zhejiang Otsuka, Chengdu Kanghong and Shanghai Sino Western pharmaceutical have obtained approval documents for pharmaceutical production At the same time, in addition to the Enhua pharmaceutical industry, there are also enterprises such as Huahai Pharmaceutical (600521 SH), Qilu pharmaceutical and hausen pharmaceutical in R & D Enhua Pharmaceutical Co., Ltd is the leader of central nervous system medicine in China The main products of the company, midazolam and risperidone, are affected by the administrative price reduction, and the product growth slows down The market hopes that the company's reserve varieties will be approved and listed, creating new performance growth points.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
